Efficacy and Safety of Rifaximin-α in Treating MASLD
NCT07381257
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
DRUG:
Rifaximin-α (Alfa Wassermann S.p.A., Italy)
Sponsor
Shanghai Changzheng Hospital